Clinical trials: Malignant Melanoma
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Malignant Melanoma
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received…
- Trial name
- NCT00864253
- Testing
- ABI-007, Dacarbazine
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 529 people
- Sponsor
- Celgene
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Melanoma
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells.
- Trial name
- NCT00522834
- Testing
- Elesclomol (STA-4783), Paclitaxel
- Where
- 101 sites in United States, Australia and 6 more
- Volunteers
- 630 people
- Sponsor
- Synta Pharmaceuticals Corp.
Stage II Melanoma
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a…
- Trial name
- Neo ReNi II (NCT05418972)
- Testing
- Relatlimab and nivolumab fixed dose combination (FDC)
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Melanoma Institute Australia
Malignant Melanoma
A Pilot Study of Pivanex in Patients With Malignant Melanoma
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
- Trial name
- NCT00087477
- Testing
- Pivanex
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Titan Pharmaceuticals
Melanoma, Advanced Non Small Cell Lung Cancer
Long-Term Follow-Up Study of Patients Receiving ATL001
This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847) or Study ATX-ME-001…
- Trial name
- NCT04785365
- Testing
- Biological: ATL001
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Achilles Therapeutics UK Limited
Metastatic Melanoma
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab.
- Trial name
- IMMUNONIVO (NCT03225365)
- Testing
- Blood and biopsy sampling
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Neoplasms
Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer
Dendritic cells loaded with tumor antigens induce cytotoxic T-cells which have been proved capable of killing both melanoma and breast cancer cells. Melanoma and colorectal cancer cells express some common antigens.
- Trial name
- NCT00311272
- Testing
- MelCancerVac
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Recurrent Melanoma
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery.
- Trial name
- KPT-330 (NCT02120222)
- Testing
- selinexor, Correlative studies
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kari Kendra
Lung Cancer
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
This research study is studying cryoablation (a treatment to kill cancer cells with extreme cold) combined with continued treatment with current immune checkpoint inhibitor as a possible treatment for lung cancer.
- Trial name
- NCT03290677
- Testing
- Cryoablation, Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted…
- Trial name
- NCT06870994
- Testing
- Targeted Hyperthermia Therapy
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Malignant Melanoma, Breast Cancer
Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and…
- Trial name
- NCT03060356
- Testing
- T cells modified with RNA anti -cMET CAR
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Pennsylvania
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs.
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer
- Trial name
- NCT01590069
- Testing
- Aerosolized Aldesleukin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Uveal Melanoma
Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients
PROQEM is a prospective cohort study among patients diagnosed with uveal melanoma to assess quality of life before and in the first five years after treatment.
- Trial name
- PROQEM (NCT05377957)
- Testing
- Quality of life questionnaires, Discrete choice experiment, Shared decision-making analysis
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Leiden University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.